tHEORetically Speaking
Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/
tHEORetically Speaking
Weekly News Roundup – Obesity Drug Rivalry, Rare Disease Pathways, Vaccine Mandate Battles, and ACA Shake-Ups
•
HealthEconomics.com
•
Season 4
•
Episode 12
This week’s tHEORetically Speaking News Roundup covers Novo’s Wegovy showing superior cardiovascular benefits over Lilly’s Zepbound, the FDA’s new Rare Disease Evidence Principles to accelerate ultra-rare drug development, and Florida’s move to abolish vaccine mandates. We also explore HHS’s expansion of catastrophic health plans amid looming ACA premium hikes.
Tune in for this concise recap of these pivotal industry updates!